Nyxoah Implants First Patient in BREATHE US Post-Approval Study of Genio System

Shots: Nyxoah announced the first patient implantation in BREATHE, its US post-approval study evaluating the long-term safety and effectiveness of the Genio System in adults with moderate to severe obstructive sleep apnea (OSA) The prospective, multicenter study plans to implant up to 229 pts. across up to 25 US centres, with follow-up for up to…

ByPrince GiriSeptember 8, 2026

Eli Lilly to Acquire Centessa Pharmaceuticals in a Deal Valued at ~$7.8B

Shots: Eli Lilly has entered into a definitive agreement to acquire Centessa Pharmaceuticals incl. its asset cleminorexton & ORX142, expanding Lilly's neuroscience portfolio & capabilities into sleep medicine As per the deal, Lilly will acquire all issued & to-be-issued share capital of Centessa (incl. ADSs) for $38/share in cash (~$6.3B upfront), plus a non-transferable CVR of…

ByRidhi RastogiMarch 31, 2026

Alkermes to Acquire Avadel Pharmaceuticals for ~$2.1B, Marking its Entry in Sleep Medicine Market

Shots: Alkermes has entered into a definitive agreement to acquire Avadel, incl. its asset Lumryz, accelerating its entry into the sleep medicine market As per the deal, Alkermes will acquire Avadel for $18.5/share, along with one non-tradeable CVR of $1.5/share tied to Lumryz’s US FDA approval for idiopathic hypersomnia in adults by 2028 end, representing…

ByRidhi RastogiOctober 24, 2025

Nyxoah Implants First Patient in BREATHE US Post-Approval Study of Genio System

Eli Lilly to Acquire Centessa Pharmaceuticals in a Deal Valued at ~$7.8B

Alkermes to Acquire Avadel Pharmaceuticals for ~$2.1B, Marking its Entry in Sleep Medicine Market

Contact US

FOLLOW US